Gelesis, Inc.
14
0
0
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 14 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
20%
2 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
Primary Hepatobiliary Cancer Cohort of Central China
Role: collaborator
Study of Gelesis100 on Body Weight in Overweight and Obese Subjects With and Without Type 2 Diabetes
Role: lead
SATISFY (geleSis100 Effects on AppeTIte Sensations, Feeding Behavior and Dietary energY)
Role: collaborator
Effects of Gelesis200 on Appetite Parameters, Food Intake, and Glycemic Control in Overweight or Obese Prediabetic Subjects: A Sub-Study of LIGHT-UP
Role: lead
Study on GS300 on NAFLD
Role: lead
Assessing GS500 in Functional Constipation
Role: lead
Effect of Gelesis200 on Body Weight in Overweight and Obese Subjects w/o Type 2 Diabetes
Role: lead
The Effect of CSP01 on Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation
Role: collaborator
The Effect of Gelesis100 on the Pharmacokinetics of Metformin
Role: lead
Effect of GSP3 on Body Weight in Overweight and Obese Subjects
Role: lead
Extension Study of Gelesis100 on Body Weight
Role: lead
Gelesis Glycemic Index Study
Role: lead
A Scintigraphic Study to Investigate the Effect of Gelesis100 on Gastric Emptying in Overweight and Obese Subjects
Role: lead
Gelesis200 Safety and Tolerability Study and Effects on Glycemic and Appetite Parameters
Role: lead
All 14 trials loaded